• Lara K Márquez, Annick Borquez, Clara Fleiz, Carlos Magis-Rodríguez, Gudelia Rangel, Steffanie A Strathdee, and Natasha K Martin.
• Division of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, California, United States.
• Gac Med Mex. 2022 Jan 1; 158 (2): 110113110-113.

AbstractIn 2019, Mexico was one of the first countries in Latin America to commit resources to achieve hepatitis C elimination by 2030. One year after this commitment, the global COVID-19 pandemic diverted attention to address immediate health needs to combat the spread of the disease. As a result, efforts to implement hepatitis C prevention and management programs were indefinitely postponed. Furthermore, populations at high risk of contracting the hepatitis C virus (HCV) and who bear the greatest burden of HCV national epidemic, including people who inject drugs and people who live with human immunodeficiency virus infection, remain exposed to extreme health disparities, which have potentially been exacerbated during the COVID-19 pandemic. In this article, we discuss the potential impact the COVID-19 pandemic has had on HCV elimination efforts in Mexico and the urgent need to resume them, since without these efforts, HCV elimination goals are likely not be achieved in the country by 2030.Copyright: © 2022 Permanyer.

16 keywords...

hide…